Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Zymeworks is pleased to announce, along with their partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the… Read More